Search:
 
Home > AIM > Company Profiles > Fulcrum

Price

Market

Sector

Market Cap
3.00p (0.00p) 0.00% AIM Medicine and Biotech Research £5.34m
Add to company folder | Print
Articles Financial Data Charts Profile
Related Companies
AGY
 10.50p 0.00%
APH
 4.38p 20.69% Up
AZH
 p
BBI
 p
CEN
 p
CBF
 1.62p 0.00%
COT
 85.50p -7.07% Down
CRX
 2.12p -10.53% Down
CYX
 p
LAC
 p
EVC
 25.00p 0.00%
FUM
 31.00p 0.00%
GNI
 p
GWP
 31.00p 0.00%
HML
 0.60p 4.35% Up
MLR
 p
MMG
 5.88p -2.08% Down
MPM
 19.00p 0.00%

Commentary

Drug development and regulatory services

Recent Articles

How much is your CEO paid? 06/12/2005
Collaborations boost 05/05/2004
Fulcrum Pharma 20/11/2003
AIM Report 01/06/2003
Biotechnology – two sure-fire ways to profit 02/02/2003
Fulcrum Pharma 24/06/2002
Fulcrum Pharma 08/02/2002
Fulcrum could be big in Japan 15/11/2001
Fulcrum Pharma 15/11/2001
Fulcrum Pharma 16/05/2001
More

Recent Announcements

Result of AGM
 23/12/2008
Director/PDMR Shareholding
 24/11/2008
Collaboration with Quantum Solutions
 14/11/2008
Final Results
 12/11/2008
Board Changes
 26/09/2008
Director/PDMR Shareholding-Replacement
 12/09/2008
Director/PDMR Shareholding
 12/09/2008
Appointment of Director
 02/09/2008
Director/PDMR Shareholding
 05/06/2008
Interim Results
 22/05/2008
More

Articles from the Sector

Summit Corporation 07/01/2009
Arthritis decision cheers SkyePharma 07/01/2009
New arthritis test for Axis-Shield 06/01/2009
York Pharma in collaboration deal 22/12/2008
Regulator enlists Entelos 16/12/2008
Stroke hope at ReNeuron   28/11/2008
Futura Medical 28/11/2008
Option deal boosts ImmuPharma  25/11/2008
Digital imager targets AIM 24/11/2008
Vectura loses interim £11.7m 24/11/2008
More

Financial History
Financial Year End 31/08/2004 31/08/2005 31/08/2006 31/08/2007 31/08/2008
Currency GBP GBP GBP GBP GBP
Turnover 11.09 12.63 15.45 11.50 14.83
Operating Profit -1.26 -0.12 0.08 0.19 0.67
Pretax Profit -1.21 -0.08 0.09 0.15 0.45
Earnings After Tax -1.12 -0.09 0.08 0.14 0.32
Profit Available For Dividend 0.00 0.00 0.00 0.00 0.00
Ordinary Dividends -0.24 0.00 0.00 0.00 0.00
Retained Profit -1.37 0.00 0.08 0.00 0.00
Shareholders Funds 3.43 3.33 3.57 5.78 6.20
Net Current Assets 2.99 2.72 1.88 0.00 0.00
Adjusted Earnings Per Share Undiluted 0.00 0.00 0.00 0.10 0.19
Adj Earnings Per Share 0.00 0.00 0.00 0.09 0.18
Dividend Per Share 0.20 0.00 0.00 0.00 0.00

Company Details

Address Hemel One, Boundary Way, Hemel Hempstead, HP2 7YU
Telephone 01442 283 600
Fax 01442 283 613

Executives

Chairman Charles George (0.30% holding)
Chief Executive Frank Armstrong (0.30% holding)
Finance Director Geoffrey Smith (2.50% holding)
Director Alastair Devlin (4.00% holding)

Main Shareholders

Bluehone: 14.1%
Pershing Keen Nominees: 5.2%
Jonathan Court: 4.3%
Rathbone Investment Management: 4.1%

Advisers

Nominated Adviser Seymour Pierce
Nominated Broker Seymour Pierce
Solicitors Pinsent Masons
Auditors PricewaterhouseCoopers
Registrar Capita Registrars

Commentary

Drug development and regulatory services

Company Data
Code FUL
Sedol GB00022420
Shares In Issue 177.941 m
Indices Aim
Entry on AIM 15/03/2000
Interim Results May
Final Results Nov
Year End Aug
Accounts Due Nov
Int div payment n/a
Fin div payment n/a
Int net div per share nil
Fin net div per share nil
Probable CGT relief Yes